The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia

High-throughput screening has revolutionized drug development and monumentally decreased the costs associated with testing compound libraries (1). Despite such advances, there has been little change in the success rate of commercial drug development of novel therapies (1,2). While the use of tumor cell monocultures in high-throughput drug screening has been used as the conventional platform for identifying new treatments for leukemia (3), novel cancer therapeutics displaying seemingly promising in vitro efficacy from such drug screening platforms often fail to translate their expected advantages (4,5).
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Source Type: research